{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:38:43Z","timestamp":1790285923191,"version":"4.1.0"},"reference-count":164,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Salivary gland carcinomas (SGCs) represent a rare and heterogeneous group of malignancies accounting for 3\u20136% of all head and neck cancers. While surgical resection and radiotherapy remain the standard for locoregional control, systemic treatment is indicated for recurrent or metastatic disease. Advances in molecular profiling have identified actionable targets such as NTRK gene fusions, HER2, immune checkpoint regulators, androgen receptors, and RET receptors. These have facilitated the development of targeted therapies, including TRK inhibitors, HER2-directed agents, and androgen receptor modulators, as well as emerging combinations of immunotherapy and chemotherapy. Despite these advancements, challenges such as resistance mechanisms and limited therapeutic efficacy persist. Overall response rates remain relatively low across most systemic therapies, reflecting a persistent unmet clinical need. This review discusses the current landscape of treatment options and explores promising clinical trials and future directions to enhance outcomes for patients with SGCs.<\/jats:p>","DOI":"10.3390\/curroncol32040232","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:04:56Z","timestamp":1744797896000},"page":"232","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions"],"prefix":"10.3390","volume":"32","author":[{"given":"Sushanth","family":"Sreenivasan","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Allegheny Health Network, 320 East North Ave, Pittsburgh, PA 15212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1324-865X","authenticated-orcid":false,"given":"Rahim","family":"Jiwani","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"White","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli","family":"Bakalov","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Moll","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Liput","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"ref_1","first-page":"100","article-title":"Targeted therapy in salivary gland malignancies: A review of molecular insights and clinical applications","volume":"33","author":"Argiris","year":"2019","journal-title":"J. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1177\/014556131709600319","article-title":"The rising incidence of major salivary gland cancer in the United States","volume":"96","author":"Megwalu","year":"2017","journal-title":"Ear Nose Throat J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gontarz, M., Bargiel, J., G\u0105siorowski, K., Marecik, T., Szczurowski, P., Zapa\u0142a, J., and Wyszy\u0144ska-Pawelec, G. (2021). Epidemiology of primary epithelial salivary gland tumors in southern Poland\u2014A 26-year, clinicopathologic, retrospective analysis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081663"},{"key":"ref_4","first-page":"110","article-title":"Emerging targeted therapies in head and neck cancers: Focus on salivary gland tumors","volume":"58","author":"Brown","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s00432-015-1961-y","article-title":"Incidence, treatment, and outcome of parotid carcinoma, 1996\u20132011: A population-based study in Thuringia, Germany","volume":"141","author":"Wendt","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1007\/s00432-022-04278-6","article-title":"Incidence and clinical outcome of primary carcinomas of the major salivary glands: 10-year data from a population-based state cancer registry in Germany","volume":"149","author":"Nachtsheim","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3322\/caac.21807","article-title":"The evolving landscape of salivary gland tumors","volume":"73","author":"Steuer","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","first-page":"e884","article-title":"Epidemiology and treatment of adenoid cystic carcinoma of the minor salivary glands: A meta-analytic study","volume":"16","year":"2011","journal-title":"Med. Oral Patol. Oral Y Cir. Bucal"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/PAS.0b013e3182841554","article-title":"Most nonparotid \u201cacinic cell carcinomas\u201d represent mammary analog secretory carcinomas","volume":"37","author":"Bishop","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00106-005-1293-3","article-title":"Salivary gland carcinomas. 1. Epidemiology, etiology, malignancy criteria, prognostic parameters and classification","volume":"53","author":"Lang","year":"2005","journal-title":"HNO"},{"key":"ref_11","unstructured":"PDQ Adult Treatment Editorial Board (2025, March 20). Salivary Gland Cancer Treatment (PDQ\u00ae), PDQ Cancer Information Summaries [Internet], Available online: https:\/\/www.cancer.gov\/types\/head-and-neck\/hp\/adult\/salivary-gland-treatment-pdq."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00428-021-03105-6","article-title":"Malignant salivary gland tumours in families with breast cancer susceptibility","volume":"479","author":"Ripamonti","year":"2021","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_13","first-page":"89","article-title":"Molecular targets in salivary gland cancers: From bench to bedside","volume":"45","author":"Smith","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gasne, C., Atallah, S., Dauzier, E., Thariat, J., Fakhry, N., Verillaud, B., Classe, M., Vergez, S., Moya-Plana, A., and Costes-Martineau, V. (2024). Twelve years after: The french national network on rare head and neck tumours (REFCOR). Oral Oncol., 151.","DOI":"10.1016\/j.oraloncology.2024.106762"},{"key":"ref_15","first-page":"200","article-title":"Update from the 5th edition of the World Health Organization classification of head and neck tumors: Salivary glands","volume":"16","author":"Hyrcza","year":"2022","journal-title":"Head Neck Pathol."},{"key":"ref_16","first-page":"492","article-title":"Genomic landscape of salivary gland tumors: Frequent alterations in TP53, HRAS, and the PI3K pathway","volume":"208","author":"Sato","year":"2015","journal-title":"Cancer Genet."},{"key":"ref_17","first-page":"757","article-title":"Salivary duct carcinoma: Updates in histology, cytology, molecular genetics, and management","volume":"128","author":"Williams","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"ref_18","first-page":"10296","article-title":"Targeted next-generation sequencing of parotid gland cancer uncovers genetic heterogeneity and potential therapeutic targets","volume":"9","author":"Gnepp","year":"2018","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Li, Z., Li, J., Bai, X., Huang, X., and Wang, Q. (2024). Tumor microenvironment as a complex milieu driving cancer progression: A mini review. Clin. Transl. Oncol., 1\u201310.","DOI":"10.1007\/s12094-024-03697-w"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Perri, F., Fusco, R., Sabbatino, F., Fasano, M., Ottaiano, A., Cascella, M., Marciano, M.L., Pontone, M., Salzano, G., and Maiello, M.E. (2024). Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?. Cancers, 16.","DOI":"10.3390\/cancers16050970"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cleymaet, R., Vermassen, T., Coopman, R., Vermeersch, H., De Keukeleire, S., and Rottey, S. (2022). The therapeutic landscape of salivary gland malignancies\u2014Where are we now?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314891"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12935-023-03130-2","article-title":"Cancer stem cells and their niche in cancer progression and therapy","volume":"23","author":"Liu","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejrad.2008.01.027","article-title":"Imaging of salivary gland tumours","volume":"66","author":"Lee","year":"2008","journal-title":"Eur. J. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jcu.20704","article-title":"Sonographic diagnosis of parotid gland lesions: Correlation with the results of sonographically guided fine-needle aspiration biopsy","volume":"38","year":"2010","journal-title":"J. Clin. Ultrasound"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kumar, A., Khan, J., Kaur, G., Khalilullah, M., Saha, A.K., and Kumar, A. (2024). Ultrasonography-Guided Fine Needle Aspiration Cytology Versus Histopathology: Diagnostic Consistency in Salivary Gland Neoplasms. Cureus, 16.","DOI":"10.7759\/cureus.69552"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12285-015-0016-3","article-title":"Malignant salivary gland tumors","volume":"8","author":"Ettl","year":"2015","journal-title":"Der MKG-Chir."},{"key":"ref_27","first-page":"649","article-title":"Salivary gland imaging","volume":"39","year":"2011","journal-title":"J. Calif. Dent. Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Surov, A., Meyer, H.J., and Wienke, A. (2020). Apparent diffusion coefficient for distinguishing between malignant and benign lesions in the head and neck region: A systematic review and meta-analysis. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01362"},{"key":"ref_29","first-page":"240","article-title":"Clinical utility of 18F-FDG PET for patients with salivary gland malignancies","volume":"48","author":"Roh","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1309\/AJCPOIE0CZNAT6SQ","article-title":"A systematic review and meta-analysis of the diagnostic accuracy of fine-needle aspiration cytology for parotid gland lesions","volume":"136","author":"Schmidt","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.joms.2009.09.064","article-title":"Fine-needle aspiration cytology of salivary gland lesions: A systematic review","volume":"68","author":"Colella","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12105-024-01725-3","article-title":"An Institutional Experience of Core Needle Biopsy with Cooperative Implementation by Pathologists and Head and Neck Oncologists in Salivary Gland Carcinoma","volume":"18","author":"Kobayashi","year":"2024","journal-title":"Head Neck Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12105-024-01741-3","article-title":"The Impact of Lesion-Specific and Sampling-Related Factors on Success of Salivary Gland Fine-Needle Aspiration Cytology","volume":"19","author":"Mayer","year":"2025","journal-title":"Head Neck Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.4103\/jcrt.jcrt_2687_22","article-title":"Importance of radio-histo-cytopathological correlation, A retrospective study of cyto-histological and radiological correlation of salivary gland lesions using Milan System for Reporting Salivary Gland Cytopathology","volume":"20","author":"Vijayakumar","year":"2024","journal-title":"J. Cancer Res. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Magaki, S., Hojat, S.A., Wei, B., So, A., and Yong, W.H. (2019). An Introduction to the Performance of Immunohistochemistry, Springer.","DOI":"10.1007\/978-1-4939-8935-5_25"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1177\/0192623311419163","article-title":"The use of immunohistochemistry for biomarker assessment\u2014Can it compete with other technologies?","volume":"39","author":"Dunstan","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/crst.crst_284_23","article-title":"Looking through the same lens-Immunohistochemistry for salivary gland tumors: A narrative review on testing and management strategies","volume":"7","author":"Kumar","year":"2024","journal-title":"Cancer Res. Stat. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1158\/1078-0432.CCR-20-4071","article-title":"Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations","volume":"27","author":"Karpinets","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Locati, L.D., Ferrarotto, R., Licitra, L., Benazzo, M., Preda, L., Farina, D., Gatta, G., Lombardi, D., Nicolai, P., and Vander Poorten, V. (2023). Current management and future challenges in salivary gland cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1264287"},{"key":"ref_40","first-page":"681","article-title":"Diagnosis and management of parotid malignancies","volume":"275","author":"Bradley","year":"2018","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"ref_41","first-page":"707","article-title":"The role of radiotherapy in salivary gland tumors: Retrospective analysis","volume":"78","author":"Garden","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1102\/1470-7330.2007.0008","article-title":"Imaging in salivary gland diseases","volume":"7","author":"Thoeny","year":"2007","journal-title":"Cancer Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.joms.2005.03.006","article-title":"Management and outcomes of high-grade salivary gland malignancies","volume":"63","author":"Bell","year":"2005","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijrobp.2004.03.018","article-title":"The role of postoperative radiotherapy in salivary gland malignancies: A multi-institutional study","volume":"61","author":"Terhaard","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_45","unstructured":"Yom, S.S., Brizel, D.M., Pfister, D.G., and Spencer, S. (2025, March 20). Head and Neck Cancers, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network (NCCN). Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1437."},{"key":"ref_46","first-page":"960","article-title":"Proton beam therapy in head and neck cancers","volume":"36","author":"Liao","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_47","unstructured":"Rodriguez, C. (2025, March 20). A Randomized Phase II\/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors (RTOG 1008). NRG Oncology. Available online: https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/rtog-1008."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or recurrent salivary gland malignancies","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_49","first-page":"2118","article-title":"Systemic therapy in the palliative management of advanced salivary gland cancers","volume":"34","author":"Laurie","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jjco\/hyac008","article-title":"Systemic therapy for salivary gland malignancy: Current status and future perspectives","volume":"52","author":"Imamura","year":"2022","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/1097-0142(19800801)46:3<452::AID-CNCR2820460305>3.0.CO;2-Z","article-title":"Chemotherapy for adenocystic carcinoma","volume":"46","author":"Tannock","year":"1980","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.anorl.2023.11.006","article-title":"Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method","volume":"141","author":"Thariat","year":"2024","journal-title":"Eur. Ann. Otorhinolaryngol. Head Neck Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.anorl.2023.11.004","article-title":"Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method","volume":"141","author":"Sarradin","year":"2024","journal-title":"Eur. Ann. Otorhinolaryngol. Head Neck Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archotol.1981.00790480015004","article-title":"Cisplatin therapy for adenoid cystic carcinoma","volume":"107","author":"Schramm","year":"1981","journal-title":"Arch. Otolaryngol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S","article-title":"Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients","volume":"68","author":"Licitra","year":"1991","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hed.2880140403","article-title":"Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck","volume":"14","author":"Vermorken","year":"1992","journal-title":"Head Neck"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/1097-0142(19881201)62:11<2313::AID-CNCR2820621110>3.0.CO;2-4","article-title":"Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck","volume":"62","author":"Creagan","year":"1988","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/oxfordjournals.annonc.a058665","article-title":"Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Head and Neck Cancer Cooperative Group","volume":"4","author":"Vermorken","year":"1993","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ejca.2008.08.014","article-title":"Phase II study on gemcitabine in recurrent and\/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)","volume":"44","author":"Locati","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/oxfordjournals.annonc.a010770","article-title":"Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck","volume":"7","author":"Verweij","year":"1996","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00216934","article-title":"Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck","volume":"8","author":"Mattox","year":"1990","journal-title":"Investig. New Drugs"},{"key":"ref_63","first-page":"3781","article-title":"Paclitaxel and carboplatin for recurrent salivary gland malignancies","volume":"20","author":"Airoldi","year":"2000","journal-title":"Anticancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3109\/00016489.2016.1170876","article-title":"Combination chemotherapy of carboplatin and paclitaxel for advanced\/metastatic salivary gland carcinoma patients: Differences in responses by different pathological diagnoses","volume":"136","author":"Nakano","year":"2016","journal-title":"Acta Oto-Laryngol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0964-1955(97)00026-2","article-title":"Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma","volume":"33","author":"Hill","year":"1997","journal-title":"Oral Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mpo.2950160309","article-title":"Preliminary experience with chemotherapy in advanced salivary gland neoplasms","volume":"16","author":"Belani","year":"1988","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1200\/JCO.1990.8.6.1056","article-title":"Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma","volume":"8","author":"Dimery","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","article-title":"Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies","volume":"91","author":"Airoldi","year":"2001","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/COC.0000000000000112","article-title":"Cisplatin+ vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): A final report on 60 cases","volume":"40","author":"Airoldi","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4143\/crt.2021.1019","article-title":"A single-arm, prospective, phase II study of cisplatin plus weekly docetaxel as first-line therapy in patients with metastatic or recurrent salivary gland cancer","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res. Treat. Off. J. Korean Cancer Assoc."},{"key":"ref_72","first-page":"362","article-title":"A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: A trial of the NCIC Clinical Trials Group","volume":"116","author":"Laurie","year":"2010","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/his.13981","article-title":"Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion","volume":"76","author":"Xu","year":"2020","journal-title":"Histopathology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: A hitherto undescribed salivary gland tumor entity","volume":"34","author":"Skalova","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/PAS.0000000000001718","article-title":"Pan-TRK Immunohistochemistry Is Highly Correlated with NTRK3 Gene Rearrangements in Salivary Gland Tumors","volume":"45","author":"Huang","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_76","first-page":"418","article-title":"Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion","volume":"11","author":"Dunn","year":"2020","journal-title":"J. Adv. Pr. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Han, S.-Y. (2021). TRK inhibitors: Tissue-agnostic anti-cancer drugs. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070632"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1093\/oncolo\/oyac080","article-title":"Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers","volume":"29","author":"Le","year":"2022","journal-title":"Oncologist"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_81","unstructured":"(2025, March 20). A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03215511."},{"key":"ref_82","unstructured":"(2025, March 20). A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04094610."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"478","DOI":"10.6004\/jnccn.2021.7022","article-title":"Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib","volume":"19","author":"Florou","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Krzakowski, M., Lu, S., Cousin, S., Smit, E., Springfeld, C., Goto, K., Garrido, P., Chung, C., Lin, J.J., and Bray, V. (2022). Updated analysis of the efficacy and safety of entrectinib in patients with locally advanced\/metastatic NTRK fusion-positive (NTRK-FP) solid tumors. J. Clin. Oncol., 40.","DOI":"10.1200\/JCO.2022.40.16_suppl.3099"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"595","DOI":"10.25122\/jml-2021-0394","article-title":"Evaluation of HER2\/neu expression in different types of salivary gland tumors: A systematic review and meta-analysis","volume":"15","author":"Javaheripour","year":"2022","journal-title":"J. Med. Life"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Bewick, M., Chadderton, T., Conlon, M., Lafrenie, R.M., Morris, D.R., Stewart, D.A., and Gl\u00fcck, S. (1999). Expression of C-erbB-2\/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Molecular Biology of Hematopoiesis 6, Springer Science & Business Media.","DOI":"10.1007\/978-1-4615-4797-6_12"},{"key":"ref_87","first-page":"1053","article-title":"HER2 expression in salivary duct carcinoma","volume":"41","author":"Suzuki","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_88","first-page":"5400","article-title":"ERBB-2 (HER2\/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer","volume":"55","author":"Feuerstein","year":"1995","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/1078-0432.CCR-03-0253","article-title":"HER2 expression in salivary gland carcinomas","volume":"10","author":"Glisson","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2\u2013positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: Results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000488669","article-title":"Second-line treatment of HER2-positive salivary gland tumor: Ado-trastuzumab emtansine (T-DM1) after progression on trastuzumab","volume":"11","author":"Matos","year":"2018","journal-title":"Case Rep. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Filippini, D., Pagani, R., Tober, N., Lorini, L., Riefolo, M., Molinari, G., Burato, A., Alfieri, S., Bossi, P., and Presutti, L. (2023). HER2-targeted therapies for salivary gland cancers. Oral Oncol., 148.","DOI":"10.1016\/j.oraloncology.2023.106612"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A Phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Li, B.T., Shen, R., Offin, M., Buonocore, D.J., Myers, M.L., Venkatesh, A., Razavi, P., Ginsberg, M.S., Ulaner, G.A., and Solit, D.B. (2019). Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.6001"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/lio2.863","article-title":"The efficacy of PD-1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study","volume":"7","author":"Sato","year":"2022","journal-title":"Laryngoscope Investig. Otolaryngol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajco.14108","article-title":"Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer","volume":"20","author":"Nagatani","year":"2024","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: Findings of the phase 1b KEYNOTE-028 study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Niwa, K., Kawakita, D., Nagao, T., Takahashi, H., Saotome, T., Okazaki, M., Yamazaki, K., Okamoto, I., Hirai, H., and Tada, Y. (2020). Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-73965-6"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_105","unstructured":"(2025, March 15). Pemetrexed and Pembrolizumab for the Treatment of Recurrent and\/or Metastatic Salivary Gland Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04895735."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_107","unstructured":"(2025, March 20). Study of Nivolumab Plus Ipilimumab in Patients with Salivary Gland Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03172624."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Yura, Y., and Hamada, M. (2022). Oral immune-related adverse events caused by immune checkpoint inhibitors: Salivary gland dysfunction and mucosal diseases. Cancers., 14.","DOI":"10.3390\/cancers14030792"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijrobp.2020.08.018","article-title":"A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma","volume":"109","author":"Mahmood","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Dalin, M.G., Watson, P.A., Ho, A.L., and Morris, L.G. (2017). Androgen receptor signaling in salivary gland cancer. Cancers, 9.","DOI":"10.3390\/cancers9020017"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hed.23940","article-title":"Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor\u2013positive salivary gland cancers","volume":"38","author":"Locati","year":"2016","journal-title":"Head Neck"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-24-0455","article-title":"Apalutamide and goserelin for androgen receptor-positive salivary gland carcinoma: A phase 2 nonrandomized clinical trial, YATAGARASU","volume":"30","author":"Honma","year":"2024","journal-title":"Clin Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor\u2013positive salivary duct carcinoma","volume":"110","author":"Locati","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_116","first-page":"772","article-title":"Androgen receptor expression in salivary duct carcinoma: Potential diagnostic and therapeutic implications","volume":"16","author":"Honma","year":"2003","journal-title":"Mod Pathol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone acetate in patients with castration-resistant, androgen receptor\u2013expressing salivary gland cancer: A phase II trial","volume":"39","author":"Locati","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_118","unstructured":"(2025, March 20). Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-Positive Salivary Gland Carcinoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03942653."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.22.00229","article-title":"Phase II study of enzalutamide for patients with androgen receptor\u2013positive salivary gland cancers (alliance A091404)","volume":"40","author":"Ho","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.humpath.2018.08.011","article-title":"Novel gene fusions in secretory carcinoma of the salivary glands: Enlarging the ETV6 family","volume":"83","author":"Guilmette","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Lassche, G., van Helvert, S., Eijkelenboom, A., Tjan, M.J.H., Jansen, E., van Cleef, P.V., Verhaegh, G., Kamping, E., Gr\u00fcnberg, K., and van Engen-van Grunsven, A.V.E. (2022). Identification of fusion genes and targets for genetically matched therapies in a large cohort of salivary gland cancer patients. Cancers, 14.","DOI":"10.3390\/cancers14174156"},{"key":"ref_122","first-page":"2595","article-title":"Genomic landscape of 891 RET fusions detected across diverse malignancies","volume":"11","author":"Wang","year":"2020","journal-title":"Oncotarget"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Reingold, R.E., Parisi, R., Harada, G., Moy, A., Dranitsaris, G., Francis, J.H., Gounder, M., Patel, J.D., Subbiah, V., and Taylor, M.H. (2025). Mucocutaneous adverse events in cancer patients treated with selective RET kinase inhibition. JTO Clin Res Rep., 6.","DOI":"10.1016\/j.jtocrr.2025.100792"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2021.10.033","article-title":"Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and\/or metastatic salivary gland cancer","volume":"161","author":"Uijen","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Ho, A.L., Sherman, E.J., Baxi, S.S., Haque, S., Ni, A., Antonescu, C.R., Katabi, N., Morris, L.G., Chan, T.A., and Pfister, D.G. (2016). Phase II study of regorafenib in progressive, recurrent\/metastatic adenoid cystic carcinoma. J. Clin. Oncol., 34.","DOI":"10.1200\/JCO.2016.34.15_suppl.6096"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cncr.29401","article-title":"Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma","volume":"121","author":"Keam","year":"2015","journal-title":"Cancer"},{"key":"ref_128","first-page":"2394","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"384","author":"Wirth","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion\u2013positive non\u2013small-cell lung cancer (ARROW): A multi-cohort, open-label, registrational phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11864-021-00827-2","article-title":"Defining and targeting BRAF mutations in solid tumors","volume":"22","author":"Halle","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Wagner, S.A. (2022). Clinical associations and genetic interactions of oncogenic BRAF alleles. PeerJ, 10.","DOI":"10.7717\/peerj.14126"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Wendorff, T.J., Kung, J., and Sudhamsu, J. (2023). Oncogenic mutations in BRAF and MEK weaken the ATP-stabilized inactive conformation of RAF to promote RAF dimerization and MAPK pathway activation. Mol. Cancer Res., 21.","DOI":"10.1158\/1557-3125.RAS23-A036"},{"key":"ref_133","first-page":"73","article-title":"Consistent absence of BRAF mutations in salivary gland carcinomas","volume":"6","author":"Mohtasham","year":"2017","journal-title":"J. Dent. Mater. Tech."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jop.12504","article-title":"Assessment of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in benign and malignant salivary gland neoplasms","volume":"46","author":"Bodnar","year":"2017","journal-title":"J. Oral Pathol. Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Dahse, R., Kromeyer-Hauschild, K., Berndt, A., and Kosmehl, H. (2009). No Incidence of BRAF Mutations in Salivary Gland Carcinomas\u2014Implications for Anti-EGFR Therapies. BioMed Res. Int., 2009.","DOI":"10.1155\/2009\/501736"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2018.7056","article-title":"First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition","volume":"16","author":"Lin","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Gouda, M., and Subbiah, V. (2023). Expanding the Benefit: Dabrafenib\/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. Am. Soc. Clin. Oncol. Educ. Book, 43.","DOI":"10.1200\/EDBK_404770"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAF^V600E mutations: Results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tranon.2014.07.006","article-title":"c-Kit expression is rate-limiting for stem cell factor-mediated disease progression in adenoid cystic carcinoma of the salivary glands","volume":"7","author":"Phuchareon","year":"2014","journal-title":"Transl. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(00)00387-6","article-title":"Expression of the c-KIT protein is associated with certain subtypes of salivary gland carcinoma","volume":"154","author":"Jeng","year":"2000","journal-title":"Cancer Lett."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2005.06.125","article-title":"Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: A Princess Margaret Hospital phase II consortium study","volume":"23","author":"Hotte","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2005.12.026","article-title":"A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands","volume":"43","author":"Pfeffer","year":"2007","journal-title":"Oral Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.bjoms.2010.09.013","article-title":"Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma","volume":"49","author":"Ghosal","year":"2011","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdv537","article-title":"Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors","volume":"27","author":"Wong","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.semcdb.2015.09.018","article-title":"Mutational and network-level mechanisms underlying resistance to anti-cancer kinase inhibitors","volume":"50","author":"Mancini","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Ou, X., Gao, G., Habaz, I.A., and Wang, Y. (2024). Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm, 5.","DOI":"10.1002\/mco2.694"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"83","DOI":"10.17219\/acem\/64876","article-title":"Expression of VEGF165b, VEGFR1, VEGFR2, and CD34 in benign and malignant tumors of parotid glands","volume":"27","author":"Sokalski","year":"2018","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Zhu, G., Zhang, L., Dou, S., Li, R., Li, J., Ye, L., Jiang, W., Dong, M., Ruan, M., and Zhang, C. (2021). Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A single-arm, phase II prospective study. Ther. Adv. Med. Oncol., 13.","DOI":"10.1177\/17588359211013626"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/hed.25891","article-title":"Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract","volume":"41","author":"Locati","year":"2019","journal-title":"Head Neck"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-21-1061","article-title":"Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma","volume":"27","author":"Kang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Kang, H., Ahn, M., Keam, B., Bowles, D., Wong, D., Ho, A., Kim, S.B., Worden, F., Yun, T., and Jang, S. (2023). Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R\/M) adenoid cystic carcinoma (ACC). J. Clin. Oncol., 41.","DOI":"10.1200\/JCO.2023.41.16_suppl.6040"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"396","DOI":"10.21873\/invivo.13841","article-title":"Disproportionality analysis of hepatotoxic and gastrointestinal adverse events associated with nintedanib using the Japanese Adverse Drug Event Report (JADER) database","volume":"39","author":"Fujiwara","year":"2024","journal-title":"In Vivo"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4143\/crt.2023.980","article-title":"Phase 1\/2a study of rivoceranib, a selective VEGFR-2 angiogenesis inhibitor, in patients with advanced solid tumors","volume":"56","author":"Kang","year":"2024","journal-title":"Cancer Res Treat."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijom.2015.12.015","article-title":"Mutational analysis of PI3K\/AKT and RAS\/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA","volume":"45","author":"Shalmon","year":"2016","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1158\/1535-7163.MCT-05-0228","article-title":"Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model","volume":"5","author":"Younes","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT pathway in cancer: The framework of malignant behavior","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pharmthera.2014.09.006","article-title":"Targeting PI3 kinase in cancer","volume":"146","author":"Bauer","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hed.23664","article-title":"Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial","volume":"37","author":"Hoover","year":"2015","journal-title":"Head Neck"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Kim, D.W., Oh, D.Y., Shin, S.H., Kang, J.H., Cho, B.C., Chung, J.S., Kim, H.J., Park, K.U., Kwon, J.H., and Bang, Y.J. (2014). A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-795"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Tsimberidou, A., Verschraegen, C., Heestand, G., Kaleta, R., Scheuenpflug, J., Huck, B., Weise, A., and Kurzrock, R. (2015). P5.01A first in human, dose escalation trial of MSC2363318A\u2014A dual p70S6K\/Akt inhibitor, for patients with advanced malignancies. Ann. Oncol., 26.","DOI":"10.1093\/annonc\/mdv094.1"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Li, X., Dai, D., Chen, B., Tang, H., Xie, X., and Wei, W. (2018). Efficacy of PI3K\/AKT\/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomized control trials. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192464"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/17425255.2019.1663169","article-title":"Molecular basis for class side effects associated with PI3K\/AKT\/mTOR pathway inhibitors","volume":"15","author":"Zhang","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1002\/cncr.25852","article-title":"A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the Eastern Cooperative Oncology Group (E1303)","volume":"117","author":"Argiris","year":"2011","journal-title":"Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/232\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:15:48Z","timestamp":1760030148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":164,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["curroncol32040232"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32040232","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]}}}